Zoetis Inc.
NYSE: ZTS·Parsippany, New Jersey·CIK 0001555280
- Price
- $84.39
- Base IV
- $117.96
Valuation snapshot
At $84.39, the price is below even our bear case of $87.77.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $117.96
- above today's price · range $87.77–$154.73
- Price vs base case
- 28% below
- $84.39 against $117.96
- Base case · our researched forecast, 2026-11-06See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $87.77 to bull $154.73. Values per share.
Price against each value
- Bear case
- $87.77
- Price 4% below
- No growth
- …
- —
- Base case
- $117.96
- Price 28% below
What does Zoetis do?
Zoetis provides medicines, vaccines, and diagnostic products to veterinarians and producers to treat, prevent, and detect illnesses in companion animals and livestock.
It brought in $9.5B of sales in the 12 months to Sep 2026.
- Industry
- Healthcare
- Based in
- Parsippany, New Jersey
- Trades on
- NYSE as ZTS
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 26¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 28¢ of every dollar.
- Making what it sells28¢
- Research and development8¢
- Sales, marketing and admin25¢
- Everything else, including interest6¢
- Tax7¢
- Left as profit26¢
Who pays Zoetis, and for what?
Zoetis sells medicines, vaccines, diagnostic products and services, and other animal health products for pets and livestock. It earns revenue by selling these products directly and through distributors, retailers and online channels around the world.
Its direct customers include veterinarians, livestock producers and veterinary distributors; pet owners and livestock businesses are often the end users.
United States
Animal health products sold in the U.S.; reported as a geographic operating segment.
International
Animal health products sold outside the U.S.; reported as a geographic operating segment.
Companion animal products
Medicines, vaccines, diagnostics and other products for pets, mainly dogs, cats and horses.
Livestock products
Medicines, vaccines, diagnostics and other products for cattle, swine, poultry, fish and sheep.
Client Supply Services and human health products
Contract manufacturing services for other companies and human health diagnostic products.
Where its work physically happens, beyond headquarters:
- Kalamazoo Manufacturing & R&D Headquarters — Kalamazoo, United States. Zoetis's R&D headquarters shares this site with a large manufacturing plant, so the pipeline and a large share of U.S. pharmaceutical output both depend on it.
- Lincoln Manufacturing & R&D Site — Lincoln, United States. This is one of Zoetis's largest U.S. plants and also hosts R&D, and it makes key biologics (vaccines) and pharmaceuticals for both livestock and companion animals.
- Douglasville Companion Animal Biologics Plant — Douglasville, United States. This planned plant of about $590 million will make companion-animal monoclonal antibodies and vaccines, and is expected to run by 2029, adding U.S. capacity for Zoetis's fastest-growing franchises.
- Tullamore Manufacturing Site — Tullamore, Ireland. This is one of three Zoetis-operated plants in Ireland, part owned and part leased, and supplies product to international markets.
- Louvain-la-Neuve Manufacturing & R&D Site — Louvain-la-Neuve, Belgium. This European plant also hosts R&D, which links product development to supply for the international segment.
How is the business doing?
Sales grew from $6.7B in 2020 to $9.5B in 2025, about 7% a year.
After paying for its upkeep and new investment, it had $2.2B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Zoetis says it exists to support people and communities by advancing care for animals.
“To nurture our world and humankind by advancing care for animals.”
What management says it is working on now:
Advance innovation
Develop new products and improve existing ones across medicines, vaccines, diagnostics and other areas of animal health.
Zoetis 2025 Form 10-KImprove the customer experience
Connect products and services more closely and make it easier for veterinarians, livestock producers and pet owners to work with Zoetis.
Zoetis 2025 Form 10-KExpand digital and data-based solutions
Use digital tools and data to help customers make animal health and livestock production decisions.
Zoetis 2025 Form 10-KStrengthen the business
Zoetis says it is adapting its commercial approach, directing investment toward current opportunities, accelerating innovation and pursuing business development.
Zoetis Announces Second Quarter 2026 ResultsImprove efficiency and sustainability
Management describes priorities that include improving operations, supporting colleagues and reducing the business's environmental footprint.
Zoetis 2025 Form 10-K
- 2026 revenue, Full year 2026
- $9.12 billion to $9.32 billion
- Zoetis Announces Second Quarter 2026 Results
- 2026 organic operational revenue growth, Full year 2026
- Down 3% to down 1%
- Zoetis Announces Second Quarter 2026 Results
- 2026 adjusted diluted earnings per share, Full year 2026
- $6.15 to $6.25
- Zoetis Announces Second Quarter 2026 Results
- Potential blockbuster pipeline candidates, Over the coming years
- More than 12
- Zoetis Announces Second Quarter 2026 Results
What's changing right now?
Growth is slowing. In Q3 2026 it sold 1% less than a year earlier. The year before, quarters averaged 2%.
Since Oct 2026 the share price has risen 6%, from $79.62 to $84.39.
Recently
February 12, 2026
Companion animal revenue share changed to 69.6%
Zoetis 2025 Form 10-K Item 1February 12, 2026
Capital expenditure intensity changed to 6.6%
Zoetis 2025 Form 10-K Statement of Cash Flows
Coming up
November 5, 2026
Third quarter 2026 results
Zoetis is scheduled to report quarterly results and hold a webcast and conference call.
Zoetis Investor RelationsExpected in 2026
Potential 2026 product milestones
The company's April 2026 pipeline overview lists next-generation chemistry diagnostics and a long-acting version of Cytopoint as expected 2026 milestones; timing and approvals may change.
Zoetis Corporate Overview: April 2026
Our own estimate moved too: the base case went from $93.05 to $117.96 a share between our last two valuations. The biggest reason: Companion animal revenue share moved from an unreported prior value to 69.6%, as reported in Zoetis 2025 Form 10-K Item 1.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Dependence on leading products
Five leading products and product lines generated about 42% of 2025 revenue. Safety concerns, competition, supply problems or loss of customer confidence in these products could materially affect sales.
From the company's own filingsWould hit how fast sales growZoetis 2025 Form 10-K
Competition and generic alternatives
Other animal health companies and lower-priced generic products compete with Zoetis. As patents expire, competitors may win sales or pressure Zoetis to lower prices.
From the company's own filingsWould hit how fast sales growZoetis 2025 Form 10-K
Product safety and regulatory requirements
New safety or effectiveness concerns can lead to recalls, label changes or weaker demand. Product approvals and ongoing compliance also depend on rules that differ across markets.
From the company's own filingsWould hit how fast sales growZoetis 2025 Form 10-K
Customer price sensitivity and buying power
If pet owners defer veterinary care or customers choose cheaper products, demand may fall. Larger veterinary groups, distributors and retailers may also negotiate lower prices.
From the company's own filingsWould hit how fast sales growZoetis Announces Second Quarter 2026 Results
Manufacturing and supply interruptions
Some products rely on complex production or particular manufacturing sites. A production or shipping problem could delay launches, limit supply or trigger recalls and added costs.
From the company's own filingsWould hit how fast sales growZoetis 2025 Form 10-K
Livestock disease, antibiotic rules and trade
Animal disease outbreaks can reduce herd sizes and demand, though they can also increase demand for some treatments. Restrictions on livestock antibiotics or trade disruptions could also affect sales and costs.
From the company's own filingsWould hit how fast sales growZoetis 2025 Form 10-K
Full year 2025 consolidated revenue growth was restricted to 2.28% due to livestock softness and distributor inventory adjustments.
From our researchWould hit how fast sales growZoetis 2025 Form 10-K
Is it a good business?
From 2016 to 2025 it earned between 43% and 78% on its shareholders' equity, a median of 50%.
It bought back shares: the count fell 7.1% in a year, so each remaining share owns a slightly bigger slice.
It owes $7.7B more than it holds in cash. An operating-profit comparison is unavailable from the published quarters.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $84.39. Our put its value between $87.77 and $154.73, with $117.96 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $87.77
This conservative scenario assumes that Zoetis struggles with ongoing pet owner caution over its arthritis pain medications and weaker clinic visits, keeping annual sales growth sluggish at one to two percent while profits moderately soften.
Base case, $117.96
This baseline scenario assumes that veterinary clinic visits stabilize and demand for staple pet medicines recovers, allowing annual sales growth to return to four to five percent with steady profitability.
Bull case, $154.73
This optimistic scenario assumes that safety concerns around pet pain medications fade quickly while international expansion and new dermatology treatments accelerate, lifting annual sales growth to seven or eight percent alongside expanding profit margins.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects less than we do.Margin of safety: 28%
At today's $84.39, the price makes sense if sales shrink about 1.7% a year. We assume they grow 4.6%. Over the last 5 years, sales grew 4.5% a year.
Or, if sales grow 4.6% as we assume, the price works with a profit margin of 28.3% (we assume 37.5%).
Keep in mind: a low price can mean investors see a risk that isn't in the filings yet. Check the Full research tab for what could go wrong.
Do you think sales will shrink?
Try your own numbersWe're moderately sure of this range: it scores 70 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $117.96 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average4.6%
- Operating margin37.5%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$117.96 39.8%

